|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The APAC Alzheimer Therapeutics Industry Report shows that symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD. Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.
Other Key Points in Report:
The AD market has a lack of therapeutic options.
- Which classes of drug dominate the market?
- What newly approved therapies have entered the market?
- How do the leading marketed therapies compare clinically?
- How will the new therapies be positioned in the treatment of AD?
- How have selected late-stage pipeline therapies performed in clinical trials?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW00020342/buying
Table of Content: An Overview
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Etiology and Pathophysiology 14
2.5 Diagnosis 16
2.6 Disease Stages 19
2.7 Prognosis 20
2.8 Treatment Options 21
2.8.1 Treatment Algorithm 21
2.8.2 Pharmacological Treatments 23
2.8.3 Non-pharmacological Treatments 25
3 Marketed Products 26
3.1 Overview 26
3.2 Acetylcholinesterase Inhibitors 26
3.2.1 Aricept (donepezil) - Eisai 26
3.2.2 Exelon (rivastigmine) - Novartis 27
3.2.3 Razadyne (galantamine) - Janssen 27
3.2.4 Cognex (tacrine) - Shionogi 28
3.3 NMDA Receptor Antagonists 28
3.3.1 Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo 28
3.4 AChEI and NMDA Receptor Antagonists 29
3.4.1 Namzaric (memantine ER + donepezil), Actavis and Adamas 29
3.5 Heat Map - Marketed Products Overview 29
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW00020342/discount
4 Pipeline Analysis 31
4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 31
4.2 Pipeline Analysis by Mechanism of Action 33
4.3 Promising Pipeline Candidates 36
4.3.1 MK-8931- Merck 36
4.3.2 LMTX (methylthioninium chloride) - TauRX Therapeutics 37
4.3.3 Gantenerumab (RG-1540) - Roche 39
4.3.4 AZD3293 - AstraZeneca 40
4.3.5 AB1010 (masitinib) - AB Science 41
4.3.6 BIIB037 - Biogen 42
4.3.7 TTP488 - vTv Therapeutics 42
4.3.8 EVP-6124 - FORUM Pharmaceuticals 43
4.3.9 Lu AE58054 - Lundbeck 44
4.3.10 Sodium Oligomannurarate 45
4.4 Heat Map for Pipeline Products 45
5 Clinical Trial Analysis 47
5.1 Failure Rate 47
5.1.1 Overall Failure Rate 47
5.1.2 Failure Rate by Phase and Molecular Target 47
5.2 Clinical Trial Size 48
5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target 48
5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target 50
5.3 Clinical Trial Duration 52
5.3.1 Trial Duration by Stage of Development and Molecule Type 52
5.3.2 Trial Duration by Stage of Development and Molecular Target 53
5.4 Summary of Clinical Trial Metrics 55
Purchase Complete Report @ http://www.reportsweb.com/buy&RW00020342/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
